Application of DNA from mushroom Pleurotus ostreatus for cancer biotherapy: A pilot study

Experimental Oncology

Volumn 28, Issue 2, 2006, Pages 132-135

  Shlyakhovenko, V ^a   Kosak, V ^a   Olishevsky, S ^a  

^a R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

Cancer biotherapy; CpG DNA; Medicinal mushrooms; Murine Ehrlich carcinoma; NK cells; Pleurotus ostreatus

Indexed keywords

FUNGAL DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER THERAPY; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY TEST; DNA ISOLATION; DRUG ACTIVITY; DRUG ISOLATION; EHRLICH ASCITES TUMOR; FRUIT; IMMUNOMODULATION; IN VITRO STUDY; LIFESPAN; MOUSE; MUSHROOM; NATURAL KILLER CELL; NONHUMAN; PLEUROTUS OSTREATUS;

ANIMALS; CARCINOMA, EHRLICH TUMOR; CPG ISLANDS; DNA, FUNGAL; FEMALE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MALE; MICE; MICE, INBRED BALB C; PILOT PROJECTS; PLEUROTUS;

EID: 33746542505     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Chihara G. The antitumor polysaccharide Lentinan: an overview. In: Manipulation of host defence mechanisms. Aoki T, Urushizaki I, Tsubura E, eds. Excerpta Medica, 1981; 281 p.
2. Bouchers AT, Stern JS, Hackman RM. Mushrooms, tumors, and immunity. Proc Soc Exp Biol Med 1999; 221: 281-93.
3. Wasser SP, Weis A. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms, a modern perspective (review). Crit Rev Immunol 1999; 19: 65-96.
4. Wasser SP, Weis A. Medicinal properties of substances occurring in higher Basidiomycetes mushrooms: current perspectives. Int J Med Mushroom 1999; 1: 31-62.
5. Tzianabos A. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin Microbiol Rev 2000; 13: 523-33.
6. Wasser SP. Medicinal mushrooms as a source of antitumor and immunomodulating polysaccharides. Appl Microbiol Biotechnol 2002; 60: 258-74.
7. Daba AS, Ezeronye OU. Anti-cancer effect of polysaccharides isolated from higher Basidiomycetes mushrooms. Afr J Biotech 2003; 2: 672-8.
8. Lindequist U, Niedermeyer THJ, Jülich W-D. The pharmacological potential of mushrooms. eCAM 2005; 2: 285-99.
9. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Ann Rev Immunol 2002; 20: 709-60.
10. Olishevsky SV, Kozak VV, Yanish YV, Shlyakhovenko VA. Immunostimmulatory CpG DNA in cancer vaccinotherapy. Exp Oncol 2003; 25: 83-92.
11. Shlyakhovenko VA, Olishevsky SV, Kozak VV, Vanish YV, Rybalko SL. Anticancer and immunostimulatory effects of nucleoprotein fraction of Bacillus subtilis 7025 culture medium filtrate. Exp Oncol 2003; 25: 119-23.
12. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Rev Immunol 2004; 4: 1-10.
13. Nucleic acids. Isolation methods. Bowien B, Dürre R, eds. Los Angeles: Am Sci Publisher, 2003; 184 p.
14. Elia MC, DeLuca JG, Bradley MO. Significance and measurement of DNA double strand breaks in mammalian cells. Pharm Therap 1991; 51: 291-327.
15. + T cells: implications for tumor immunotherapy. Immunity 1996; 4: 555-64.
16. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds. Current protocols in molecular biology. John Wiley & Sons, 2003.
17. Olishevsky S, Kozak V, Vanish Yu, Potebnya G, Lisovenko G, Olexienko I, Mazur O, Rybalko S, Shlyakhovenko V. Characteristics of extracellular DNA containing unmethylated CpG motifs isolated from Bacillus subtilis culture medium filtrate. Exp Oncol 2004; 26: 265-70.
18. Olishevsky S, Shlyakhovenko V, Kozak V, Yanish Y. Response of different organs of immune system of mice upon administration bacterial CpG DNA. Exp Oncol 2006; 27: 290-7.
19. Shimada S, Yano O, Tokunaga T. In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn J Cancer Res 1986; 77: 808-16.
20. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-5.
21. Svrcek PS, Mojzisova J, Durove A, Benisek Z, Huska M. The immunomodulatory effect of the soluble fungal glucan (Pleurotus ostreatus) on delayed hypersensitivity and phagocytic ability of blood leucocytes in mice. Zentralbl Veterinarmed B 1996; 43: 129-35.
22. Karashige S, Akuzawa Y, Endo F. Effects of Lentinus edodes, Grifola frondosa and Pleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-butyl-N-butanolnitrosoamine. Immunopharmacol Immunotoxicol 1997; 19: 175-83.
23. Zusman I, Reifen R, Livni O, Smirnoff P, Gurevich P, Sandier B, Nyvska A, Gal R, Tendler Y, Madar Z. Role of apoptosis, proliferating cell nuclear antigen and p53 protein in chemically induced colon cancer in rats fed corncob fiber treated with the fungus Pleurotus ostreatus. Anticancer Res 1997; 17: 2105-13.
24. Gerasimenya VP, Efremenkova OV, Kamzolina OV, Bogush TA, Tolstych IV, Zennkova VA. Antimicrobial and antitoxical action of edible and medicinal mushroom Pleurotus ostreatus (Jacq,:Fr.) Kumm. extracts. Int J Med Mushrooms 2002; 4: 127-32.
25. Lakshmi B, Jose N, Ajith TA, Jananrdhanan KK. Antimutagenic activity of methanolic extract of culinary-medicinal oyster mushroom, Pleurotus ostreatus (Jacq.:Fr.) Kumm. (strain floric Eger nom. Nud.) and its protective effect against benzo[a]pyrene-induced hepatic damages. Int J Med Mushrooms 2004; 6: 139-49.
26. Bobek P, Galbav Š, Ozdǐn L. Effect of oyster mushroom (Pleurotus ostreatus) on pathological changes in dimethylhydrazine-induced rat colon cancer. Oncol Rep 1998; 5: 727-30.
27. Bobek P, Galbav Š. Hypocholesteremic and antiatherogenic effect of oyster mushroom (Pleurotus ostreatus) in rabbits. Nahrung 1999; 43: 339-42.
28. Sun S, Beard C, Jaenisch R, Jones P, Sprent J. Mitogenecity of DNA from different organisms for murine B cells. J Immunol 1997; 159: 3119-25.